News | September 28, 2021
Bal Pharma ramps up API capacity of Gliclazide
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
This project will be conducted at the “NURA,” a health screening centre that Fujifilm opened in India in February this year
Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
Cephalosporin is a bactericidal, broad-spectrum, and P-lactam antibiotic originally derived from the fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infection, strep throat, staph infections, tonsillitis, bronchitis among others
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022
The three-dose vaccine approved for EUA contains 2mg for each dose, whereas the two-dose plan will have 3mg in each dose.
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
The company plans to enter the formulation business in January 2022. It has also opened a branch in Hyderabad to trade pharmaceutical chemicals
Subscribe To Our Newsletter & Stay Updated
